Targeted Neuroprotection of Retinal Ganglion Cells Via AAV2-hSyn-NGF Gene Therapy in Glaucoma Models
The AAV2-hSyn-NGF gene therapy offers a safe and effective neuroprotective strategy for RGCs across multiple glaucoma models, making it a promising candidate for future clinical trials in patients with glaucoma.
Authors
- Xiaojing Pan (ORCID: https://orcid.org/0000-0003-1882-5361)
- Qingjun Zhou (ORCID: https://orcid.org/0000-0002-7770-9275)
- Benxiang Qi (ORCID: https://orcid.org/0009-0008-6784-8707)
- Xinlei Zhu (ORCID: https://orcid.org/0000-0002-4317-3767)
- Lin William Cong (ORCID: https://orcid.org/0000-0002-2617-2367)
- Bi Ning Zhang (ORCID: https://orcid.org/0000-0002-4308-3729)
- Z.Y. Ren (ORCID: https://orcid.org/0009-0005-5095-3226)
- Lixin Xie
Institutions
- Qingdao University (CN)
- Shandong Eye Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1167/iovs.66.4.48
- Citations
- 4
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 6.83